Overview
DOACs Post-Revascularization - Can We Decrease Major Adverse Limb Events (MALE) and Improve Outcomes?
Click the"View Activity" button to view this activity.
View ActivityActivity already occured. CME/CE is no longer available for this activity
Dr. Marc Bonaca, Dr. Sean Lyden and Dr. Raghu Kolluri discuss how to properly incorporate direct oral anticoagulants (DOACs) into treatment plans for patients with peripheral artery disease (PAD). They evaluate the latest data on DOAC therapy and provide strategies for treating and protecting against thrombotic events in patients with PAD post-revascularization.
This activity is intended for vascular surgeons, interventional cardiologists, clinical cardiologists, and other healthcare providers who care for patients with peripheral vascular disease.
Because US peripheral artery disease (PAD) guidelines have not yet been updated, clinicians may not yet be familiar with the groundbreaking VOYAGER PAD study just published in May 2020 which showed that the addition of rivaroxaban to aspirin reduced risk of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes. It is critical for vascular surgeons, interventional cardiologists, and other healthcare providers who care for patients with PAD to understand the latest data to ensure that their patients receive the best possible care and mitigate further complications.
Upon completion of this activity, participants will be able to:
• Interpret the latest data on DOACs in PAD post-revascularization
• Optimize anticoagulant therapy for patients with PAD post-revascularization
• Interpret the latest data on DOACs as mono- or combination therapy to develop strategies for treating and protecting against thrombotic events
Sponsored by the Cleveland Clinic Center for Continuing Education
Academy for Continued Healthcare Learning (ACHL) is the educational partner.
Supported by an educational grant from Janssen Scientific Affairs, LLC.
Marc Bonaca, MD, MPH
Executive Director, CPC
Professor of Medicine, Cardiology & Vascular Medicine
Director of Vascular Research
University of Colorado SOM
Aurora, CO
Executive Director, CPC
Professor of Medicine, Cardiology & Vascular Medicine
Director of Vascular Research
University of Colorado SOM
Aurora, CO
Sean Lyden, MD
Department Chair, Vascular Surgery
Cleveland Clinic
Cleveland, OH
Raghu Kolluri, MD, MS, RVT, FSVM
System Medical Director
Vascular Medicine & Vascular Laboratories
OhioHealth Heart & Vascular
Clinical Professor of Medicine
Ohio University HCOM
President, Syntropic Core Lab
Columbus, OH
The following financial relationships have been provided:
Marc Bonaca, MD, MPH
Sources of Funding for Research/Independent Contractor: Amgen, ARCA BioPharm , AstraZeneca, Janssen, Lexicon, NovoNordisk,
Consulting Agreements: Amgen, AstraZeneca, Audentes Pharmaceuticals, Cook, Janssen, Lexicon, Merck, NovoNordisk, PhaseBio Pharmaceuticals, Regeneron, Sanifit, Wraser
Sean Lyden, MD
Consulting Agreements: Abbott Vascular, Boston Scientific, Centerline Biomedical, Endologix, Intact Vascular, Medtronic, Penumbra, Inc., Philips Healthcare, PQ Bypass, Inc., Shockwave Medical, Inc.
Board Membership: VIVA Physicians
Raghu Kolluri, MD, MS, RVT, FSVM
Consulting Agreements: Abbott Vascular, Boston Scientific, Inari Medical, Medtronic, Penumbra, Inc., Philips Healthcare, Surmodics, Vesper
CEC Member: Mercator Medsystem, Inc.
Steering Committee (for a clinical trial): Penumbra, Inc.
Data and Safety Monitoring Board: Thrombolex
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
Cleveland Clinic Center for Continuing Education and ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
In support of improving patient care, Cleveland Clinic Center for Continuing Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Cleveland Clinic Center for Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
